Neuronetics Amends Credit Agreement with MidCap Financial Trust
Ticker: STIM · Form: 8-K · Filed: Aug 13, 2024 · CIK: 1227636
| Field | Detail |
|---|---|
| Company | Neuronetics, Inc. (STIM) |
| Form Type | 8-K |
| Filed Date | Aug 13, 2024 |
| Risk Level | low |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $0.01, $0.0846, $4,250,000, $1,000,000, $1,900,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: credit-agreement, amendment, financing
TL;DR
Neuronetics just tweaked its loan terms with MidCap Financial Trust. No big drama, just an amendment.
AI Summary
On August 11, 2024, Neuronetics, Inc. entered into a Material Definitive Agreement, specifically a Second Amendment to its Credit Agreement with MidCap Financial Trust. This amendment modifies certain terms of their existing credit facility.
Why It Matters
This amendment to Neuronetics' credit agreement could impact its financial flexibility and future borrowing capacity.
Risk Assessment
Risk Level: low — The filing details an amendment to an existing credit agreement, which is a routine financial maneuver and does not inherently signal significant new risks.
Key Players & Entities
- Neuronetics, Inc. (company) — Registrant
- MidCap Financial Trust (company) — Lender in Credit Agreement
- August 11, 2024 (date) — Date of Material Definitive Agreement
FAQ
What specific terms were amended in the Credit Agreement?
The filing states that the Second Amendment to the Credit Agreement was entered into, but does not detail the specific terms that were modified.
What is the purpose of this Second Amendment?
The filing does not explicitly state the purpose of the Second Amendment, only that it was entered into on August 11, 2024.
Does this amendment involve any new debt or equity issuance?
The filing indicates an amendment to an existing credit agreement, not a new debt or equity issuance, though it is filed under 'Unregistered Sales of Equity Securities' which may require further review of the full document.
Who is MidCap Financial Trust in relation to Neuronetics?
MidCap Financial Trust is the lender under the Credit Agreement that Neuronetics has amended.
What is the effective date of this amendment?
The earliest event reported is August 11, 2024, which is the date of the Material Definitive Agreement.
Filing Stats: 4,485 words · 18 min read · ~15 pages · Grade level 20 · Accepted 2024-08-13 08:56:54
Key Financial Figures
- $0.01 — nge on which registered Common Stock ($0.01 par value) STIM The Nasdaq Global M
- $0.0846 — e Market Price is less than or equal to $0.0846 (the " Minimum Price "), a cash payment
- $4,250,000 — ransaction expenses not having exceeded $4,250,000, (xiii) aggregate cash taxes arising in
- $1,000,000 — lement of Greenbrook debt not exceeding $1,000,000 and (ix) Greenbrook average number of d
- $1,900,000 — ics, respectively, a termination fee of $1,900,000. The representations, warranties and
Filing Documents
- d883705d8k.htm (8-K) — 61KB
- d883705dex21.htm (EX-2.1) — 1097KB
- d883705dex101.htm (EX-10.1) — 89KB
- d883705dex102.htm (EX-10.2) — 18KB
- d883705dex103.htm (EX-10.3) — 97KB
- d883705dex104.htm (EX-10.4) — 190KB
- 0001193125-24-199454.txt ( ) — 1963KB
- stim-20240811.xsd (EX-101.SCH) — 3KB
- stim-20240811_lab.xml (EX-101.LAB) — 17KB
- stim-20240811_pre.xml (EX-101.PRE) — 11KB
- d883705d8k_htm.xml (XML) — 3KB
02. Unregistered Sales of Equity Securities
Item 3.02. Unregistered Sales of Equity Securities. The information set forth under Item 1.01 of this Current Report on Form 8-K is hereby incorporated into this Item 3.02. Neuronetics securities issued in connection with the Arrangement are expected to be issued in reliance upon an exemption from registration under federal securities laws provided by Section 3(a)(10) of the Securities Act for the issuance and exchange of securities approved after a public hearing on the fairness of the terms and conditions of the exchange by a court of competent jurisdiction at which all persons to whom the securities will be issued have the right to appear. The Arrangement will be subject to approval by the Court. Neuronetics anticipates that, if the Arrangement becomes effective under the terms and conditions set forth in the Arrangement Agreement (including receipt of the final order from the approval by the Court), the Consideration Shares to be issued pursuant to the Arrangement will be exempt from the registration requirements of the Securities Act pursuant to Section 3(a)(10) thereof. "Safe harbor" statement under the Private Securities Litigation Reform Act of 1995: This document includes "forward-looking statements" within the meaning of Section 27A of the Securities Act, Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created by those laws and other applicable laws and "forward-looking information" within the meaning of applicable Canadian securities laws. Statements in the press release that are not historical facts constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by terms such as "outlook," "potential," "believe," "expect," "plan," "anticipate," "predict," "may," "will," "could," "would" and "should" as well as the negative of these terms and similar expressions. These statement